

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**

---

**FINANCIAL STATEMENTS  
AND  
REPORTS UNDER THE UNIFORM GUIDANCE**

**Years Ended December 31, 2024 and 2023**

## TABLE OF CONTENTS

| Description   | Pages   |
|---|---------|
| Independent Auditors' Report  | 1 – 3   |
| Statements of Financial Position  | 4       |
| Statements of Activities  | 5 - 6   |
| Statements of Functional Expenses   | 7 - 8   |
| Statements of Cash Flows  | 9       |
| Notes to Financial Statements   | 10 – 21 |
| Schedule of Expenditures of Federal Awards  | 22      |
| Notes to Schedule of Expenditures of Federal Awards   | 23      |
| Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> | 24 – 25 |
| Independent Auditors' Report on Compliance for Each Major Program and on Internal Control Over Compliance Required by the Uniform Guidance  | 26 – 28 |
| Schedule of Findings and Questioned Costs   | 29 – 30 |
| Summary Schedule of Prior Audit Findings  | 31      |



**RUBINO**

STRENGTH IN NUMBERS

## INDEPENDENT AUDITORS' REPORT

To the Board of Directors  
Syrian American Medical Society Foundation

### ***Opinion***

We have audited the accompanying financial statements of Syrian American Medical Society Foundation (a nonprofit organization), which comprise the statements of financial position as of December 31, 2024 and 2023, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Syrian American Medical Society Foundation as of December 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### ***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Syrian American Medical Society Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

### ***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Syrian American Medical Society Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

## ***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Syrian American Medical Society Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Syrian American Medical Society Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

## **Other Matters**

### *Other Information*

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards, as required by Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the financial statements as a whole.

### ***Other Reporting Required by Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated June 5, 2025, on our consideration of Syrian American Medical Society Foundation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Syrian American Medical Society Foundation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Syrian American Medical Society Foundation's internal control over financial reporting and compliance.



Bethesda, Maryland  
June 5, 2025

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**STATEMENTS OF FINANCIAL POSITION**  
**December 31, 2024 and 2023**

|   | <u>2024</u>          | <u>2023</u>          |
|---|----------------------|----------------------|
| <b>ASSETS</b>                           |                      |                      |
| Cash and cash equivalents               | \$ 7,418,417         | \$ 24,789,301        |
| Investments                             | 17,148,559           | 6,879,443            |
| Grants and contributions receivable     | 6,185,873            | 5,910,672            |
| Other receivables                       | 422,368              | 90,469               |
| Medical student loans receivable        | 120,077              | 143,203              |
| Prepaid expenses and other assets       | 334,399              | 285,000              |
| Property and equipment, net             | 2,061,319            | 2,018,058            |
| Operating lease right-of-use asset, net | <u>50,935</u>        | <u>88,522</u>        |
| Total assets                            | <u>\$ 33,741,947</u> | <u>\$ 40,204,668</u> |
| <b>LIABILITIES AND NET ASSETS</b>       |                      |                      |
| Accounts payable and accrued expenses   | \$ 3,376,323         | \$ 4,069,618         |
| Refundable advances                     | 2,224,620            | 3,454,182            |
| Operating lease liability               | <u>61,559</u>        | <u>105,823</u>       |
| Total liabilities                       | <u>5,662,502</u>     | <u>7,629,623</u>     |
| Net assets                              |                      |                      |
| Without donor restrictions              | 27,363,659           | 24,144,463           |
| With donor restrictions                 | <u>715,786</u>       | <u>8,430,582</u>     |
| Total net assets                        | <u>28,079,445</u>    | <u>32,575,045</u>    |
| Total liabilities and net assets        | <u>\$ 33,741,947</u> | <u>\$ 40,204,668</u> |

The accompanying notes are an integral part of these financial statements.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**STATEMENT OF ACTIVITIES**  
**Year Ended December 31, 2024**

|                                       | Without Donor<br>Restrictions | With Donor<br>Restrictions | Total                       |
|---------------------------------------|-------------------------------|----------------------------|-----------------------------|
| Support and revenue                   |                               |                            |                             |
| Grants                                | \$ 28,211,701                 | \$ -                       | \$ 28,211,701               |
| Contributions                         | 5,816,945                     | 3,573,681                  | 9,390,626                   |
| In-kind contributions                 | 25,346,094                    | -                          | 25,346,094                  |
| Net assets released from restrictions | 11,288,477                    | (11,288,477)               | -                           |
| Total support and revenue             | <u>70,663,217</u>             | <u>(7,714,796)</u>         | <u>62,948,421</u>           |
| Expenses                              |                               |                            |                             |
| Program                               |                               |                            |                             |
| Medical relief program                | 65,574,974                    | -                          | 65,574,974                  |
| Total program                         | <u>65,574,974</u>             | <u>-</u>                   | <u>65,574,974</u>           |
| Supporting services                   |                               |                            |                             |
| Management and general                | 1,646,790                     | -                          | 1,646,790                   |
| Fundraising                           | 1,390,157                     | -                          | 1,390,157                   |
| Total supporting services             | <u>3,036,947</u>              | <u>-</u>                   | <u>3,036,947</u>            |
| Total expenses                        | <u>68,611,921</u>             | <u>-</u>                   | <u>68,611,921</u>           |
| Change in operating net assets        | 2,051,296                     | (7,714,796)                | (5,663,500)                 |
| Other income                          | 26,828                        | -                          | 26,828                      |
| Investment income                     | 1,141,072                     | -                          | 1,141,072                   |
| Change in net assets                  | 3,219,196                     | (7,714,796)                | (4,495,600)                 |
| Net assets, beginning of year         | <u>24,144,463</u>             | <u>8,430,582</u>           | <u>32,575,045</u>           |
| Net assets, end of year               | <u><u>\$ 27,363,659</u></u>   | <u><u>\$ 715,786</u></u>   | <u><u>\$ 28,079,445</u></u> |

The accompanying notes are an integral part of these financial statements.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**STATEMENT OF ACTIVITIES**  
**Year Ended December 31, 2023**

|                                       | Without Donor<br>Restrictions | With Donor<br>Restrictions | Total                       |
|---------------------------------------|-------------------------------|----------------------------|-----------------------------|
| Support and revenue                   |                               |                            |                             |
| Grants                                | \$ 33,833,011                 | \$ -                       | \$ 33,833,011               |
| Contributions                         | 11,228,060                    | 16,726,138                 | 27,954,198                  |
| In-kind contributions                 | 40,337,567                    | -                          | 40,337,567                  |
| Net assets released from restrictions | 8,412,603                     | (8,412,603)                | -                           |
| Total support and revenue             | <u>93,811,241</u>             | <u>8,313,535</u>           | <u>102,124,776</u>          |
| Expenses                              |                               |                            |                             |
| Program                               |                               |                            |                             |
| Medical relief program                | <u>82,371,226</u>             | -                          | <u>82,371,226</u>           |
| Total program                         | <u>82,371,226</u>             | -                          | <u>82,371,226</u>           |
| Supporting services                   |                               |                            |                             |
| Management and general                | 1,490,246                     | -                          | 1,490,246                   |
| Fundraising                           | <u>1,406,972</u>              | -                          | <u>1,406,972</u>            |
| Total supporting services             | <u>2,897,218</u>              | -                          | <u>2,897,218</u>            |
| Total expenses                        | <u>85,268,444</u>             | -                          | <u>85,268,444</u>           |
| Change in operating net assets        | 8,542,797                     | 8,313,535                  | 16,856,332                  |
| Other income                          | 500                           | -                          | 500                         |
| Investment income                     | <u>364,234</u>                | -                          | <u>364,234</u>              |
| Change in net assets                  | 8,907,531                     | 8,313,535                  | 17,221,066                  |
| Net assets, beginning of year         | <u>15,236,932</u>             | <u>117,047</u>             | <u>15,353,979</u>           |
| Net assets, end of year               | <u><u>\$ 24,144,463</u></u>   | <u><u>\$ 8,430,582</u></u> | <u><u>\$ 32,575,045</u></u> |

The accompanying notes are an integral part of these financial statements.



**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**STATEMENT OF FUNCTIONAL EXPENSES**  
**Year Ended December 31, 2024**

|   | <u>Program Services</u>      | <u>Supporting Services</u> |                     |                                 |                      |
|---|------------------------------|----------------------------|---------------------|---------------------------------|----------------------|
|   | Medical<br>Relief<br>Program | Management<br>and General  | Fundraising         | Total<br>Supporting<br>Services | Total                |
| Salaries, wages, and benefits                     | \$ 25,236,832                | \$ 1,099,585               | \$ 287,279          | \$ 1,386,864                    | \$ 26,623,696        |
| Assistance in foreign operations                  | 3,505,863                    | -                          | -                   | -                               | 3,505,863            |
| Medical equipment, supplies, and services         | 30,045,011                   | -                          | -                   | -                               | 30,045,011           |
| Fuel  | 491,119                      | -                          | -                   | -                               | 491,119              |
| Supplies and stationary                           | 737,958                      | 5,984                      | 3,637               | 9,621                           | 747,579              |
| Travel and transportation                         | 745,363                      | 32,107                     | 3,969               | 36,076                          | 781,439              |
| Rent, utilities, and maintenance                  | 2,618,232                    | 45,422                     | 3,730               | 49,152                          | 2,667,384            |
| Contracted services                               | 1,116,227                    | 187,299                    | 106,491             | 293,790                         | 1,410,017            |
| Postage and printing                              | 9,411                        | 2,022                      | 303,719             | 305,741                         | 315,152              |
| Advertising                                       | 25,114                       | -                          | 78,486              | 78,486                          | 103,600              |
| Conference, convention, and meetings              | 99,517                       | 14,625                     | 245,249             | 259,874                         | 359,391              |
| Bank fees   | 371,509                      | 20,906                     | 109,480             | 130,386                         | 501,895              |
| Scholarships, dues, subscriptions, and membership | 452,678                      | 103,862                    | 185,635             | 289,497                         | 742,175              |
| Storage and shipping                              | 59,297                       | 42,011                     | 88                  | 42,099                          | 101,396              |
| Information, technology, and software             | 60,843                       | 92,967                     | 62,394              | 155,361                         | 216,204              |
| Total expenses                                    | <u>\$ 65,574,974</u>         | <u>\$ 1,646,790</u>        | <u>\$ 1,390,157</u> | <u>\$ 3,036,947</u>             | <u>\$ 68,611,921</u> |

The accompanying notes are an integral part of these financial statements.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**STATEMENT OF FUNCTIONAL EXPENSES**  
**Year Ended December 31, 2023**

|   | <u>Program Services</u>      | <u>Supporting Services</u> |                     |                                 |                      |
|---|------------------------------|----------------------------|---------------------|---------------------------------|----------------------|
|   | Medical<br>Relief<br>Program | Management<br>and General  | Fundraising         | Total<br>Supporting<br>Services | Total                |
| Salaries, wages, and benefits                     | \$ 23,360,746                | \$ 984,631                 | \$ 322,348          | \$ 1,306,979                    | \$ 24,667,725        |
| Assistance in foreign operations                  | 3,710,022                    | 384                        | 11,261              | 11,645                          | 3,721,667            |
| Medical equipment, supplies, and services         | 48,422,302                   | -                          | -                   | -                               | 48,422,302           |
| Fuel  | 594,719                      | -                          | -                   | -                               | 594,719              |
| Supplies and stationary                           | 1,295,185                    | 25,774                     | 4,589               | 30,363                          | 1,325,548            |
| Travel and transportation                         | 976,916                      | 30,436                     | 11,634              | 42,070                          | 1,018,986            |
| Rent, utilities, and maintenance                  | 2,454,290                    | 34,535                     | 2,155               | 36,690                          | 2,490,980            |
| Contracted services                               | 772,379                      | 213,603                    | 59,671              | 273,274                         | 1,045,653            |
| Postage and printing                              | 21,265                       | 2,355                      | 341,314             | 343,669                         | 364,934              |
| Advertising                                       | 53,057                       | 1,817                      | 49,110              | 50,927                          | 103,984              |
| Conference, convention, and meetings              | 23,433                       | 2,232                      | 213,385             | 215,617                         | 239,050              |
| Bank fees   | 377,659                      | 21,898                     | 335,795             | 357,693                         | 735,352              |
| Scholarships, dues, subscriptions, and membership | 216,147                      | 10,773                     | 434                 | 11,207                          | 227,354              |
| Storage and shipping                              | 43,343                       | 28,226                     | 78                  | 28,304                          | 71,647               |
| Information, technology, and software             | 49,763                       | 133,582                    | 55,198              | 188,780                         | 238,543              |
|   | <u>\$ 82,371,226</u>         | <u>\$ 1,490,246</u>        | <u>\$ 1,406,972</u> | <u>\$ 2,897,218</u>             | <u>\$ 85,268,444</u> |
| Total expenses                                    | <u>\$ 82,371,226</u>         | <u>\$ 1,490,246</u>        | <u>\$ 1,406,972</u> | <u>\$ 2,897,218</u>             | <u>\$ 85,268,444</u> |

The accompanying notes are an integral part of these financial statements.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**STATEMENTS OF CASH FLOWS**  
**Years Ended December 31, 2024 and 2023**

|   | <u>2024</u>         | <u>2023</u>          |
|---|---------------------|----------------------|
| Cash flows from operating activities                |                     |                      |
| Change in net assets                                | \$ (4,495,600)      | \$ 17,221,066        |
| Reconciling adjustments                             |                     |                      |
| Depreciation and amortization                       | 3,166               | 4,744                |
| Unrealized and realized investment gain             | (666,716)           | (352,455)            |
| Amortization of operating lease right-of-use asset  | 37,587              | 130,339              |
| Donated stocks                                      | (127,797)           | (42,850)             |
| Changes in operating assets and liabilities:        |                     |                      |
| Grants and contributions receivable                 | (275,201)           | 1,229,236            |
| Other receivables                                   | (331,899)           | -                    |
| Medical student loans receivable                    | 23,126              | (49,396)             |
| Prepaid expenses and other assets                   | (49,399)            | 254,563              |
| Accounts payable and accrued expenses               | (693,295)           | 740,975              |
| Refundable advances                                 | (1,229,562)         | (1,522,909)          |
| Operating lease liability                           | <u>(44,264)</u>     | <u>(134,271)</u>     |
| Net cash (used in) provided by operating activities | <u>(7,849,854)</u>  | <u>17,479,042</u>    |
| Cash flows from investing activities                |                     |                      |
| Purchases of property and equipment                 | (46,427)            | (2,017,247)          |
| Proceeds from sale of investments                   | 1,301,566           | 128,353              |
| Purchases of investments                            | <u>(10,776,169)</u> | <u>(5,132,232)</u>   |
| Net cash used in investing activities               | <u>(9,521,030)</u>  | <u>(7,021,126)</u>   |
| Net change in cash and cash equivalents             | (17,370,884)        | 10,457,916           |
| Cash and cash equivalents, beginning of year        | <u>24,789,301</u>   | <u>14,331,385</u>    |
| Cash and cash equivalents, end of year              | <u>\$ 7,418,417</u> | <u>\$ 24,789,301</u> |

The accompanying notes are an integral part of these financial statements.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**1. Organization**

The Syrian American Medical Society Foundation (“the Foundation”) is a nonprofit, nonpolitical educational and humanitarian organization established in 2007. The mission of the Foundation is to be a global medical relief organization that is working on the front lines of crisis relief in Syria, in neighboring countries, and beyond to save lives and alleviate suffering. The Foundation proudly provides medical care and treatment to every patient in need. The Foundation also provides assistance and loans to medical students and interns of Syrian descent. The activities of the Foundation are mostly funded through grants and contributions, and through donated goods and services. The Foundation has foreign field offices in Syria, Jordan, Lebanon, Turkey, Iraq, Ukraine, and Greece.

**2. Summary of Significant Accounting Policies**

*Basis of Presentation*

The financial statements of the Foundation have been prepared in accordance with U.S. generally accepted accounting principles, which require the Foundation to report information regarding its financial position and activities according to the following net asset classifications:

**Net assets without donor restrictions:** Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation’s management and the board of directors.

**Net assets with donor restrictions:** Net assets subject to stipulations imposed by donors and grantors. The Foundation reports grants and contributions restricted by donors as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor-restricted grants and contributions are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

*Measure of Operations*

The statement of activities reports all changes in net assets, including changes in net assets from operating and nonoperating activities. Operating activities consist of those items attributable to the Foundation’s ongoing services. Nonoperating activities are limited to resources that generate return from investments and other activities considered to be of a more unusual or nonrecurring nature.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**2. Summary of Significant Accounting Policies (continued)**

*Cash and Cash Equivalents*

The Foundation considers as cash equivalents all highly liquid investments, which can be converted into known amounts of cash and have a maturity period of 90 days or less at the time of purchase. Excluded from this definition of cash equivalents are amounts held for investments.

*Investments*

Investments are recorded at fair value based on quoted market prices. Donated securities are recorded at fair value on the date the securities are received. Realized and unrealized gains and losses, net of investment management fees, are reported in net investment return in the accompanying statements of activities. Money market and short-term investment funds, held as a portion of the Foundation's investment portfolio, are not considered to be cash equivalents for purposes of cash flows.

*Grants and Contributions Receivable*

Grants and contributions receivable represent program expenditures incurred and submitted for approval, in excess of the receipt of funds from the grantor organizations. Grants and contributions receivable that are expected to be collected within one year are recorded at net realizable value. Grants and contributions receivable that are expected to be collected in future years are recorded at the net present value of their estimated future cash flows. All grants and contributions receivable were collectible in less than one year and fully collectible as of December 31, 2024 and 2023.

*Medical Student Loans Receivable*

Medical student loans receivable represents the remaining balance due on small loans made to many medical students. The original loans ranged from \$1,000 to \$4,000 each, and installment payments are recorded as they are received. The face amount of medical student loans receivable is reduced by an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of probable losses, determined principally on the basis of historical experience and allowances for specifically identified delinquent accounts. All accounts, or portions thereof, that are deemed uncollectible, or that require an excessive collection cost, are written off to the allowance for doubtful accounts. At December 31, 2024 and 2023, management deems all medical student loans receivable to be fully collectible, and no allowance for uncollectible accounts was established.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**2. Summary of Significant Accounting Policies (continued)**

*Property and Equipment*

Property and equipment acquisitions with a cost in excess of \$500 and a projected useful life exceeding one year are capitalized and recorded at cost. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the individual assets, which range from three to five years. Leasehold improvements are stated at cost and are amortized using the straight-line method over the shorter of their estimated useful lives or the term of the lease. Repair and maintenance costs are expensed as incurred.

*Operating Lease*

The Foundation determines if an arrangement is a lease at inception. Operating lease is included in right-of-use (“ROU”) assets, which represent the Foundation’s right to use an underlying asset for the lease term, and lease liabilities represent the Foundation’s obligation to make lease payments arising from the lease. Operating ROU lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Foundation’s leases do not provide an implicit rate, the Foundation used a risk-free rate based on the information available at the commencement date in determining the present value of lease payments.

The ROU assets also include any lease payments made and exclude lease incentives. The Foundation’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Foundation will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Foundation has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less.

*Refundable Advances*

Grant receipts that are in excess of matching grant expenses for the year are recognized as refundable advances in the accompanying statements of financial position.

*Functional Allocation of Expenses*

The costs of providing various programs and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services directly benefited, or based upon management’s estimates of the proportion of these costs applicable to each function.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**2. Summary of Significant Accounting Policies (continued)**

*Revenue Recognition*

The Foundation recognizes grants and contributions when cash, securities, or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give, that is, those with a measurable performance or other barrier, and a right of return, are not recognized until the conditions on which they depend have been met. Contributions received and unconditional promises to give are measured at their fair values and are recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor-imposed restrictions. The Foundation reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets, or if they are designated as support for future periods. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Donor-restricted contributions whose restrictions are met in the same reporting period are reported as unrestricted support.

A portion of the Foundation's revenue is derived from cost-reimbursable government grants, which are conditioned upon certain performance requirements and/or the incurrence of allowable qualifying expenses. Amounts received are recognized as revenue when the Foundation has incurred expenditures in compliance with specific grant provisions plus allowable indirect costs. Revenue recognized on these grants and on grants for which billings have not been presented to, or collected from, the awarding agency is included in grants and contributions receivable in the accompanying statements of financial position. Amounts received prior to incurring qualifying expenditures are reported as refundable advances in the statements of financial position.

*In-Kind Contributions*

The value of contributions, which are considered specialized and can be estimated, and would have been purchased if not donated, that enhance a nonfinancial asset, are reflected in the accompanying statements of activities as in-kind contributions. In-kind contributions consist of medical supplies, and equipment and services provided by doctors, nurses, and other medical professionals that benefit both program and supporting services. In-kind contributions are recognized as revenue and expense in the accompanying statements of activities at their estimated fair value, as provided by the donor, at the date of receipt.

*Advertising Costs*

Advertising costs are expensed as incurred.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**2. Summary of Significant Accounting Policies (continued)**

*Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

*Reclassifications*

Certain reclassifications of amounts previously reported have been made to the accompanying financial statements to maintain consistency between periods presented. The reclassifications had no impact on previously reported net assets.

*Subsequent Events*

In preparing these financial statements, the Foundation has evaluated events and transactions for potential recognition or disclosure through June 5, 2025, the date the financial statements were available to be issued.

**3. Availability and Liquidity**

The Foundation regularly monitors liquidity required to meet its annual operating needs and other contractual commitments, while also striving to preserve the principal and return on the investment of its funds.

The Foundation has various sources of liquidity at its disposal, including cash and cash equivalents, and investments, which are available for general expenditures, liabilities, and other obligations as they come due. Management is focused on sustaining the financial liquidity of the Foundation throughout the year. This is done through monitoring and reviewing the Foundation's cash flow needs on a weekly basis.

As a result, management is aware of the cyclical nature of the Foundation's cash flow related to the Foundation's various funding sources and is therefore able to ensure that there is cash available to meet current liquidity needs. As part of its liquidity plan, excess cash is invested in publicly-traded investment vehicles, including mutual funds, and equity securities, or to support organizational initiatives. The Foundation can liquidate its investments anytime, and therefore the investments are available to meet current cash flow needs.



**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

**3. Availability and Liquidity (continued)**

Financial assets available for general expenditures, that is, without donor or other restrictions limiting their use, within one year of the statements of financial position date, comprise the following at December 31:

|  | <u>2024</u>          | <u>2023</u>          |
|--|----------------------|----------------------|
| Financial assets at year end                           |                      |                      |
| Cash and cash equivalents                              | \$ 7,418,417         | \$ 24,789,301        |
| Investments  | 17,148,559           | 6,879,443            |
| Grants and contributions receivable                    | 6,185,873            | 5,910,672            |
| Other receivables                                      | 422,368              | 90,469               |
| Medical student loans receivable                       | <u>120,077</u>       | <u>143,203</u>       |
| Total financial assets                                 | 31,295,294           | 37,813,088           |
| Less amounts not available to be used within one year: |                      |                      |
| Net assets with donor restrictions                     | <u>(715,786)</u>     | <u>(8,430,582)</u>   |
| Financial assets available to meet cash needs for      |                      |                      |
| general expenditures within one year                   | <u>\$ 30,579,508</u> | <u>\$ 29,382,506</u> |

**4. Concentrations of Risk**

*Credit Risk*

Financial instruments that potentially subject the Foundation to significant concentrations of credit risk consist of cash and cash equivalents, and investments. The Foundation maintains cash deposit and transaction accounts, along with investments, with various financial institutions and these values, from time to time, exceed insurable limits under the Federal Deposit Insurance Corporation (FDIC) and Securities Investor Protection Corporation (SIPC). The uninsured portions of these accounts are backed solely by the asset of the underlying financial institution. Therefore, the failure of an underlying institution could result in financial loss for the Foundation. The Foundation has not experienced any credit losses on its cash and cash equivalents, and investments to date as it relates to FDIC and SIPC insurance limits. Management periodically assesses the financial condition of these financial institutions and believes that the risk of any credit loss is minimal.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**4. Concentrations of Risk (continued)**

*Revenue Risk*

During the years ended December 31, 2024 and 2023, approximately 40% and 41% of the Foundation's revenue and support were derived from cooperative and grant agreements with federal government agencies, respectively. Any significant reduction in revenue and support may adversely impact the Foundation's financial position and operations.

During 2025, the U.S. federal government experienced uncertainty surrounding budget appropriations, which affected various government-funded programs, including those administered by the U.S. Agency for International Development (USAID). As a result, there were interruptions and uncertainties related to the timing and availability of funding for certain program activities. The Foundation has evaluated the potential impact of these disruptions and, while operations were not materially affected as of December 31, 2024, future delays or reductions in funding may affect the scope or timing of program delivery and related revenue recognition. Management continues to monitor developments and is in communication with funding agencies to assess and respond to any ongoing risks.

*Foreign Operations*

The Foundation has field offices in Turkey, Jordan, Iraq, Lebanon, Syria, Ukraine and Greece for its programmatic purposes. The future results of the Foundation's programs could be adversely affected by a number of potential factors, such as changes in foreign banking laws or changes in the political climate of these countries. The Foundation maintains a majority of its cash in these foreign field offices in U.S. dollars.

As of December 31, 2024, the cash in foreign field offices totaled \$1,845,318, which represents approximately 6% of the Foundation's total assets. As of December 31, 2023, the cash in foreign field offices totaled \$4,358,150, which represents approximately 11% of the Foundation's total assets. The cash held in foreign field offices is held by foreign financial institutions and is not insured by FDIC.

**5. Net assets**

Net assets with donor restrictions in the amount of \$715,786 and \$8,430,582 were restricted for relief efforts at December 31, 2024 and 2023, respectively.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

**6. Investment and Fair Value Measurements**

The Foundation follows FASB ASC 820, Fair Value Measurements and Disclosures, for its financial assets. This standard establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value measurement standards require an entity to maximize the use of observable inputs (such as quoted prices in active markets) and minimize the use of unobservable inputs (such as appraisals or other valuation techniques) to determine fair value. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the entity's perceived risk of that instrument.

The inputs used in measuring fair value are categorized into three levels as follows:

- *Level 1:* Inputs that utilize unadjusted quoted prices in active markets for identical assets or liabilities that the Society has the ability to access at the measurement date.
- *Level 2:* Inputs other than quoted prices included in Level 1 that are observable for the assets or liabilities, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets or liabilities in active markets, as well as inputs that are observable for the assets or liabilities (other than quoted prices), such as interest rates, foreign exchange rates and yield curves that are observable at commonly quoted intervals.
- *Level 3:* Inputs that are unobservable for the assets or liabilities, which are typically based on an entity's own assumptions, as there is little, if any, related market activity.

The following table presents the Foundation's fair value hierarchy for those investments measured on a recurring basis at December 31, 2024 and 2023:

| <u>December 31, 2024</u>          | <u>Total</u>         | <u>Level 1</u>      | <u>Level 2</u> | <u>Level 3</u> |
|-----------------------------------|----------------------|---------------------|----------------|----------------|
| Equities                          | \$ 1,751,914         | \$ 1,751,914        | \$ -           | \$ -           |
| Mutual Funds                      | 670,957              | 670,957             | -              | -              |
| Investments carried at fair value | 2,422,871            | <u>\$ 2,422,871</u> | <u>\$ -</u>    | <u>\$ -</u>    |
| Money market funds - at cost      | 14,725,688           |                     |                |                |
| Total                             | <u>\$ 17,148,559</u> |                     |                |                |
| <u>December 31, 2023</u>          | <u>Total</u>         | <u>Level 1</u>      | <u>Level 2</u> | <u>Level 3</u> |
| Equities                          | \$ 1,244,803         | \$ 1,244,803        | \$ -           | \$ -           |
| Mutual Funds                      | 553,483              | 553,483             | -              | -              |
| Investments carried at fair value | 1,798,286            | <u>\$ 1,798,286</u> | <u>\$ -</u>    | <u>\$ -</u>    |
| Money market funds - at cost      | 5,081,157            |                     |                |                |
| Total                             | <u>\$ 6,879,443</u>  |                     |                |                |

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

**6. Investment and Fair Value Measurements (continued)**

The availability of observable market data is monitored to assess the appropriate classification of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the transfer is reported as of the end of the reporting period. For the years ended December 31, 2024 and 2023, there were no significant transfers in or out of levels 1, 2, or 3.

The following is a description of the valuation methodologies used for investments measured at fair value:

- *Mutual funds*: Valued at net asset value of shares held by the Foundation at year-end.
- *Equities*: Valued using quoted prices on active markets.

The Foundation's investments are exposed to various risks, such as interest rate and market fluctuations. Due to the level of risk associated with investment securities, changes in the values of investment securities will occur in the near term, and such changes could materially affect the Foundation's financial position.

Net investment return consists of the following for the years ended December 31:

|                                  | <u>2024</u>         | <u>2023</u>       |
|----------------------------------|---------------------|-------------------|
| Interest and dividends           | \$ 513,233          | \$ 30,400         |
| Realized and unrealized gain     | 666,468             | 352,455           |
| Less: investment management fees | <u>(38,629)</u>     | <u>(18,621)</u>   |
| Investment income                | <u>\$ 1,141,072</u> | <u>\$ 364,234</u> |

**7. Retirement Plan**

The Foundation sponsors a Simple IRA plan (the Plan) for all employees who meet the eligibility requirements. Under the provisions of the Plan, any employees who have received at least \$5,000 in compensation are eligible to participate, subject to age limitations. The Plan provides for employee voluntary contributions and employer matching contributions. The employer match is currently 100% of employee contributions up to 3% of compensation. Pension expense for the years ended December 31, 2024 and 2023, was \$31,707 and \$24,961, respectively.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**8. Property and Equipment**

Property and equipment as of December 31, 2024 and 2023, are comprised of the following:

|   | <u>2024</u>                | <u>2023</u>                |
|---|----------------------------|----------------------------|
| Furniture and fixtures                    | \$ 45,637                  | \$ 45,637                  |
| Office equipment                          | 88,876                     | 78,936                     |
| Leasehold improvements                    | 107,560                    | 107,560                    |
| Land                                      | <u>2,050,403</u>           | <u>2,013,916</u>           |
|   | 2,292,476                  | 2,246,049                  |
| Accumulated depreciation and amortization | <u>(231,157)</u>           | <u>(227,991)</u>           |
| Property and equipment, net               | <u><u>\$ 2,061,319</u></u> | <u><u>\$ 2,018,058</u></u> |

Depreciation and amortization expense for the years ended December 31, 2024 and 2023, was \$3,166 and \$4,744, respectively.

**9. Related Party Transactions**

The Syrian American Medical Society (SAMS) established the Foundation as a separate charitable corporation. SAMS has an agreement with the Foundation, whereby the Foundation provides support to SAMS in recognition of SAMS's efforts and contribution toward the costs of conferences. During the years ended December 31, 2024 and 2023, the Foundation provided \$100,000 support to SAMS for those activities each year.

**10. Commitments and Contingencies**

Government Audits

The Foundation receives funding through cooperative agreements and grants with departments and agencies of the Federal government that are subject to compliance audits by the grantors or their representatives. The disallowance of costs could adversely affect the Foundation's financial condition. Management believes that adjustments, if any, by government auditors for prior years will not be material to the financial statements.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

**10. Commitments and Contingencies (continued)**

Operating Leases

*Washington, D.C. Office*

The Foundation maintains an operating lease for office space in Washington, D.C., which expires on April 30, 2026. Future minimum lease commitments as of December 31, 2024, are as follows:

|                               |    |                |
|-------------------------------|----|----------------|
| Year ending December 31, 2025 | \$ | 48,792         |
| 2026                          |    | 16,397         |
|                               |    | <u>65,189</u>  |
| Less: imputed interest        |    | <u>(3,630)</u> |
|                               | \$ | <u>61,559</u>  |

Supplemental qualitative information related to the office lease is as follows at and for the year ended December 31, 2024:

|  |    |        |
|--|----|--------|
| Operating lease cost   | \$ | 40,924 |
| Cash paid for amounts included in the measurement of lease liabilities | \$ | 47,602 |
| Weighted-average remaining lease term (in years)                       |    | 1.3    |
| Weighted-average discount rate   |    | 3.89%  |

*Foreign Offices*

The Foundation leases office spaces, warehouses, and storage units in its foreign field offices. The leases for field offices are either on a month-to-month basis, or for a term of less than 12 months. Field offices rent expense under the operating lease agreements totaled \$895,810 and \$829,883 for the years ended December 31, 2024 and 2023, respectively.

There were no material restrictions or covenants imposed and the Foundation has no related party leases at December 31, 2024 and 2023.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO FINANCIAL STATEMENTS**  
**Years Ended December 31, 2024 and 2023**

---

**11. In-Kind Contributions**

The Foundation received the following donated goods and services, which have been reflected as in-kind contributions in the accompanying statements of activities for the years ended December 31:

|  | <u>2024</u>          | <u>2023</u>          |
|--|----------------------|----------------------|
| Donated medical equipment and supplies | \$ 23,253,594        | \$ 38,104,819        |
| Donated medical services               | <u>2,092,500</u>     | <u>2,232,748</u>     |
| Total in-kind contributions            | <u>\$ 25,346,094</u> | <u>\$ 40,337,567</u> |

**12. Allocation of Expenses from Management and General Activities**

The financial statements report certain categories of expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. All costs incurred directly for a certain function or program are coded directly and split among those activities. The expenses that are allocated include occupancy, insurance, office supplies, utilities, depreciation and amortization, salaries and wages, benefits, and payroll taxes, which are allocated on the basis of estimates of time and effort.

**13. Income Taxes**

The Foundation is exempt from payment of taxes on income other than net unrelated business income under Section 501(c)(3) of the Internal Revenue Code (IRC). For the years ended December 31, 2024 and 2023, there was no unrelated business income and, accordingly, no federal or state income taxes have been recorded. Contributions to the Foundation are deductible as provided in IRC Section 170(b)(1)(A)(vi). Management has evaluated the Foundation's tax positions and concluded that the Foundation's financial statements do not include any uncertain tax positions.

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended December 31, 2024**

| <u>Federal Agency/Pass-Through Agency/Contract Name</u>             | <u>Federal<br/>Assistance Listing<br/>Number</u> | <u>Grant Identification<br/>Number</u> | <u>Federal<br/>Expenditures</u> | <u>Amount provided<br/>to Subrecipients</u> |
|---|--|--|---------------------------------|---|
| <b><u>U.S. Agency for International Development</u></b>             |  |  |                                 |   |
| <i>Pass-through Award from Relief International, Inc.:</i>          |  |  |                                 |   |
| USAID Foreign Assistance for Programs Overseas                      | 98.001   | RI-4039-03                             | \$ 688,982                      | \$ -  |
| USAID Foreign Assistance for Programs Overseas                      | 98.001   | RI-4033-01                             | 5,454,386                       | -   |
| <b>Total U.S. Agency for International Development</b>              |  |  | <u>6,143,368</u>                | <u>-</u>                                    |
| <b><u>U.S. Department of State</u></b>                              |  |  |                                 |   |
| International Programs to Support Democracy, Human Rights and Labor | 19.345   | SLAMQM22CA0248                         | 467,973                         | 104,436                                     |
| International Programs to Support Democracy, Human Rights and Labor | 19.345   | SAQMIP23GR0215                         | 1,063,048                       | 547,167                                     |
| Total ALN 19.345  |  |  | <u>1,531,021</u>                | <u>651,603</u>                              |
| Overseas Refugee Assistance Program for Near East and South Asia    | 19.519   | SPRMCO24CA0131                         | 915,345                         | 333,317                                     |
| Overseas Refugee Assistance Program for Near East and South Asia    | 19.519   | SPRMCO23CA0157                         | 2,152,303                       | 802,990                                     |
| Total ALN 19.519  |  |  | <u>3,067,648</u>                | <u>1,136,307</u>                            |
| Nonproliferation and Disarmament Fund                               | 19.224   | SISNDF23GR0008                         | 554,225                         | -   |
| <b>Total U.S. Department of State</b>                               |  |  | <u>5,152,894</u>                | <u>1,787,910</u>                            |
| Total Expenditures of Federal Awards                                |  |  | <u>\$ 11,296,262</u>            | <u>\$ 1,787,910</u>                         |



**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**NOTES TO SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**  
**Year Ended December 31, 2024**

---

**A. Basis of Presentation**

The accompanying schedule of expenditures of federal awards (SEFA) includes the federal award activity of Syrian American Medical Society Foundation (the Foundation) under programs of the federal government for the year ended December 31, 2024. The information in SEFA is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* (CFR) Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). The principal estimates and assumptions used in the preparation of SEFA relate to cost allowability and allocability (Note B). Actual results could differ from those estimates. Because SEFA presents only a selected portion of the operations of the Foundation, it is not intended to, and does not, present the financial position, changes in net assets, or cash flows of the Foundation.

**B. Federal Audits**

The allowability of certain costs under government grants is subject to audit by the contracting agency. Certain indirect costs charged to grants are subject to revisions based on government audits of those costs. Management believes that costs are consistent with applicable government cost principles, and that costs subsequently disallowed, if any, upon audit by the government would not be material.

**C. Summary of Significant Accounting Policies**

Expenditures reported on SEFA are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

**D. Indirect Cost Rate**

The Foundation has elected to use the 10-percent de minimis indirect cost rate allowed under the Uniform Guidance.

**E. Reconciliation to Financial Statements**

Reconciliation between federal expenditures per the SEFA and grants and contributions revenue per the accompanying statement of activities for the year ended December 31, 2024 is as follows:

|  |                      |
|--|----------------------|
| Federal expenditures per SEFA            | \$ 11,296,262        |
| Add: non-federal grants                  | <u>16,915,439</u>    |
| Total grants per statement of activities | <u>\$ 28,211,701</u> |



**INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS***

To the Board of Directors  
Syrian American Medical Society Foundation

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Syrian American Medical Society Foundation (the Foundation), which comprise the statement of financial position as of December 31, 2024, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated June 5, 2025.

**Report on Internal Control over Financial Reporting**

In planning and performing our audit of the financial statements, we considered the Foundation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Foundation's internal control.

A *deficiency* in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

## Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Foundation's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Foundation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Foundation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

A handwritten signature in black ink that reads "Rubins & Company". The signature is written in a cursive, flowing style.

Bethesda, Maryland  
June 5, 2025



## **INDEPENDENT AUDITORS' REPORT ON COMPLIANCE FOR EACH MAJOR PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE**

To the Board of Directors  
Syrian American Medical Society Foundation

### **Report on Compliance for Each Major Federal Program**

#### ***Opinion on Each Major Federal Program***

We have audited Syrian American Medical Society Foundation's compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Foundation's major federal programs for the year ended December 31, 2024. The Foundation's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, Syrian American Medical Society Foundation complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2024.

#### ***Basis for Opinion on Each Major Federal Program***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Syrian American Medical Society Foundation and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Syrian American Medical Society Foundation's compliance with the compliance requirements referred to above.

### ***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to Syrian American Medical Society Foundation's federal programs.

### ***Auditor's Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Syrian American Medical Society Foundation's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Syrian American Medical Society Foundation's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Syrian American Medical Society Foundation's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Syrian American Medical Society Foundation's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Syrian American Medical Society Foundation's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

## Report on Internal Control over Compliance

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



Bethesda, Maryland  
June 5, 2025

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**SCHEDULE OF FINDINGS AND QUESTIONED COSTS**  
**Year Ended December 31, 2024**

**SECTION A – SUMMARY OF AUDITORS’ RESULTS**

*Financial Statements*

Type of auditors’ report issued: Unmodified

Internal control over financial reporting:

- Material weakness(es) identified? \_\_\_\_\_ Yes \_\_\_X\_\_\_ No
- Significant deficiencies identified that are not considered to be material weaknesses? \_\_\_\_\_ Yes \_\_\_X\_\_\_ None reported

Noncompliance material to financial statements noted? \_\_\_\_\_ Yes \_\_\_X\_\_\_ No

*Federal Awards*

Internal control over major programs:

- Material weakness(es) identified? \_\_\_\_\_ Yes \_\_\_X\_\_\_ No
- Significant deficiencies identified that are not considered to be material weakness(es)? \_\_\_\_\_ Yes \_\_\_X\_\_\_ None reported

Type of auditors’ report issued on compliance for major federal programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? \_\_\_\_\_ Yes \_\_\_X\_\_\_ No

Identification of major programs:

| <u>Description</u>  | <u>Federal Assistance Listing No.</u> | <u>Expenditures</u> |
|---|---------------------------------------|---------------------|
| U.S. Department of State:   |                                       |                     |
| Overseas Refugee Assistance Program for Near East and South Asia        | 19.519                                | \$ 3,067,648        |
| Nonproliferation and Disarmament Fund                                   | 19.224                                | \$ 554,225          |
| Dollar threshold used to distinguish between Type A and type B programs |                                       | \$750,000           |
| Auditee qualified as low-risk auditee?                                  | ___X___ Yes                           | _____ No            |

**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**SCHEDULE OF FINDINGS AND QUESTIONED COSTS**  
**Year Ended December 31, 2024**

---

**SECTION B – FINANCIAL STATEMENT FINDINGS**

None reported

**SECTION C – FEDERAL AWARD FINDINGS AND QUESTIONED COSTS**

None reported



**SYRIAN AMERICAN MEDICAL SOCIETY FOUNDATION**  
**SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS**  
**Year Ended December 31, 2024**

---

This schedule is not applicable as there were no audit findings in the prior year.